MedTrace Logo

Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI

NCT00517478 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2007-08-17

No results posted yet for this study

Summary

Determine usefulness of thromboelastography (TEG) as a valuable tool in ex-vivo assessing platelet response to aspirin and clopidogrel (dual) treatment and on-treatment platelet reactivity during acute ST segment elevation myocardial infarction (STEMI) in an acute phase during primary PCI (PPCI) and also during recovery been on maintenance medical therapy and to determine the correlation between platelet response to clopidogrel treatment and the outcome of patients.

Conditions

Interventions

PROCEDURE

Blood Sample

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • Alex Blatt, MD · Cardiology Division, Assaf Harofeh Medical Center

  • Ilia Litovchik, MD · Cardiology Division, Assaf Harofeh Medical Center

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2008-02-29

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00517478 on ClinicalTrials.gov